We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Abbott Laboratories | NYSE:ABT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.20 | 0.19% | 106.49 | 111 | 09:21:41 |
From May 2023 to May 2024
By Sabela Ojea
Abbott Laboratories said it has received positive results from its chronic limb-threatening ischemia trial and it expects to submit the drug for review by the U.S. Food and Drug Administration.
The medical devices and health care company on Wednesday said the trial met both primary safety and effectiveness endpoints and showed that its Esprit BTK drug reduces disease progression.
Chronic limb-threatening ischemia is a form peripheral arterial disease, which causes an accumulation of plaque in the arteries in legs or arms.
About 22 million people worldwide have been affected by chronic limb-threatening ischemia.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
October 25, 2023 15:02 ET (19:02 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Abbott Laboratories Chart |
1 Month Abbott Laboratories Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
